Shares of Amgen Inc. AMGN slipped 1.37% to $272.05 Thursday, on what proved to be an all-around positive trading session for ...

It’s been 19 months since Amgen completed its $27.8 billion acquisition of Horizon Therapeutics, and the California company ...

Amgen on Thursday said its first-quarter profit rose 24%, handily exceeding Wall Street expectations, as product sales ...

Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past ...

The U.K. drug regulator on Wednesday approved Amgen’s (NASDAQ:AMGN) intravenous medication teprotumumab (Tepezza) as the ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...

The stable outlook reflects S&P Global Ratings’ expectation that Amgen’s revenue and EBITDA will remain stable despite patent ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Biotech company Amgen (NASDAQ:AMGN) announced better-than-expected revenue in Q1 CY2025, with sales up 9.4% year on year to ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Amgen has announced a significant expansion of the Ohio manufacturing facility in the US, with an investment of $900m.